Published on : Feb 17, 2017
ALBANY, NY, Feb 17, 2017: The report has extensively analyzed the cervical cancer market and number of patients with the disease in North America, specifically in countries such as the U.S. and Canada. The forecast years considered in this study span from 2016 through 2020 while the review period is 2008–2015.
All of the two economies of North America analyzed in the Canada and U.S. cervical cancer screening market and patients report are evaluated according to three viewpoints, viz. population, mortality, and screening. Considering the screening aspect, each country is examined as per the overall screening or test market forecast and forecast for Pap smear and human papillomavirus (HPV) DNA test market. Likewise, the U.S. and Canada markets are evaluated according to the forecast of the overall population for cervical cancer test and also exclusively for HPV DNA and Pap smear test.
The preface of the report deems both these tests as the most common methods of testing cervical cancer in North America. It further points out the dominance of the U.S. market as it holds the potential to lead the North America region. With more than 90.0% share secured by the U.S. alone in terms of testing population, the country is projected to sustain its dominance in the North America market throughout the forecast period. Some of the demand in the U.S. market is also accredited to the regular Pap smear tests conducted for women.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=948213
For a better understanding of the market, the authors of the publication have prepared a separate section where the population share and market share for cervical cancer test in the entire North America region is considered. It also includes the market share and forecast for each of the two tests under study.
On a global platform, there have been an increasing number of cases where teenagers are involved in sexual activities. Thus, the augmenting incidence of teenage sexual cases has provided a strong boost to the North America cervical cancer screening market. The analysts have also predicted the rising prevalence of HPV infected patients as the other major driver in the North America market. One of the critical challenges of cervical cancer screening is elevating the availability of HPV vaccination.
The report has compiled decisive insights and data with the help of comprehensive secondary and primary research and proprietary databases. While the primary sources incorporate special opinions from key industry leaders, the secondary research was used to collect data from different non-printable and printable sources. More assistance has been taken from in-house analysis for putting forth valuable information pertaining to the growth and sustenance of the North America cervical cancer screening market.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org